CXM: Cardium Investor Relations email.
I bought a bit more today because I am confident Cardium is going to make significant news in March on at least one front and maybe others as well.
Excerpt from IR:
"As we have reported, we are planning for the market introduction of Excellagen, which is expected in first quarter ending March 31, 2012 and the initiation of the Generx ASPIRE late stage/registration study which is expected in the first quarter ending March 31, 2012. In addition, we plan to further expand our MedPodium Nutra-Apps product portfolio with additional product offerings and broadening distribution of the brand platform nationally and into the food, drug and mass markets"
NOTE: Imo, CXM looking very good here. Funding in place. A nice spot to ease in to position.
